A Phase 2 interventional study of TAK-128 in Diabetic Neuropathies, sponsored by Takeda. Terminated. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-02-28.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
The purpose of this study is to determine the safety of TAK-128, once daily (QD), for treatment of diabetic peripheral neuropathy
Polyneuropathy is a frequent complication of diabetes; it affects most individuals after prolonged hyperglycemia, and diabetic neuropathy is very common in the developed world. Chronic, insidious, distal sensorimotor polyneuropathy with autonomic impairment is the most typical form of diabetic neuropathy. Less common, but more florid presentations include autonomic symptoms or painful neuropathy. Although many patients have no or relatively few symptoms, the chronic polyneuropathy and autonomic dysfunction predispose to neurotrophic foot ulceration; consequently, diabetes is the leading cause of amputation today.
Diabetic neuropathy is a dying-back polyneuropathy with distal degeneration of the longest nerve fibers advancing in a centripetal direction. Multiple histopathological changes are observed, but progressive fiber loss is the hallmark of diabetic polyneuropathy. Other important features include endothelial cell basement membrane thickening, segmental demyelination and remyelination, and axonal atrophy. Similar pathological changes are observed in type 1 and type 2 diabetes. The severity of neuropathy as indicated by the stage of nerve fiber loss determines the clinical, electrophysiological, and quantitative sensory threshold features of this disorder. The functional measures of electrophysiological and quantitative sensory thresholds reflect the morphological changes and the clinical features.
Diabetic polyneuropathy is etiologically related to prolonged hyperglycemia with multiple consequences. Although strict glycemic control prevents neuropathy in type 1 patients if maintained for many years, similar interventions in those with type 2 diabetes mellitus are less successful. Type 2 patients may have neuropathy with considerable nerve fiber loss at the time of diagnosis because of unsuspected hyperglycemia in preceding years. Reversal of established neuropathy with strict glycemic control is not certain to occur, even if maintained for many years. Co-morbid disease often interferes with strict management of type 2 diabetes. Even among those with type 1 diabetes, a minority of patients are successful in maintaining prolonged euglycemia.
TAK-128 is a novel synthetic compound being developed as a treatment for diabetic neuropathy. Subjects participating in this study successfully completed Protocol 01-04-TL-128-003, and earlier study of TAK-128.
1,003 studies on the registry are indexed under Peripheral Nervous System Diseases; 177 are open to participants now.
This study's enrollment of 221 is above the median of 60 across 768 interventional studies indexed under Peripheral Nervous System Diseases.
Browse Peripheral Nervous System Diseases studies →Takeda is the lead sponsor of 1,002 studies on the registry; 92 are open to participants now.
Of its 173 completed or terminated interventional studies of FDA-regulated products, 149 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Cannot use any of the following prescription medications throughout the duration of the study, including:
Drug: TAK-128
TAK-128 100 mg tablet, orally, once daily for up to 1 year.
Treatment-emergent adverse events, vital signs and physical examination findings.
Time frame: At each visit
Clinical Laboratory Tests (Hematology, Chemistry and Urinalysis).
Time frame: At each visit
Electrocardiogram results.
Time frame: At each visit
Weight.
Time frame: At each visit
Change from Baseline in composite nerve conduction velocities (Electrophysiologic Studies).
Time frame: Months 6 and 12 or Final Visit
Change from Baseline in the electrophysiologic parameters for individual nerves, including amplitudes (Nerve Conduction Studies).
Time frame: Months 6 and 12 or Final Visit
Change from Baseline in vibration perception threshold measurements (Quantitative Sensory Testing).
Time frame: Month 3, 6, 9 and 12 or Final Visit
Change from Baseline in neurological examination (Clinical Neurologic Examination).
Time frame: Month 3, 6, 9 and 12 or Final Visit
Change from Baseline in pain scores (Short-Form McGill Pain Questionnaire).
Time frame: Month 3, 6, 9 and 12 or Final Visit
Change from Baseline in quality of life index as assessed by the Short-Form, 36-Item Health Survey.
Time frame: Month 3, 6, 9 and 12 or Final Visit
No study locations are listed for this record.
This study is terminated, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peripheral Nervous System Diseases→
Takeda